Inflazome Gains Highly Commended Recognition for its Series B Fundraise at the 2019 European Lifestars Awards™

November 22, 2019

Dublin (IE), Cambridge (UK), Brisbane (AU) | 22 November 2019: Inflazome (, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, is pleased to announce that it has been recognised with a highly commended accolade within the Series B Finance Raise of the Year award at the 2019 Lifestars Awards.™

In November 2018, Inflazome announced the successful completion of a Series B financing round of €40 million ($46 million). The financing round was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.

Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that have played a critical role in the advancement of the industry over the last 12 months, across Europe. The international awards bring together hundreds of global life science leaders, investors and deal makers and key stakeholders from the wider eco-system to recognise the achievements of the industry.



Dr Jeremy Skillington | VP Business Development



FTI Consulting

UK & International | Ciara Martin/Tim Stamper

T: +44 20 37271000

Ireland & International | Jonathan Neilan/Patrick Berkery

T: +353 1 7650800



If you are a member of the media and have a media query please contact:

Contact Us

Speak to us about
a better tomorrow

Contact Us